PATENT CLAIM ANALYSIS

Application Number: 15918788
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-07
Patent Classification: ["424", "185100"]

Abstract:
A method of eliciting an immune response in a patient who has a cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize the cancer cells in the patient that aberrantly express a peptide consisting of the amino acid sequence of GVYDGEEHSV (SEQ ID NO: 303), in which the peptide is in a complex with an MHC molecule.

Claim (Index 1):
A method of eliciting an immune response in a patient who has a cancer, comprising administering to said patient a composition comprising a population of activated T cells that selectively recognize the cancer cells in the patient, wherein the cancer cells aberrantly express a peptide consisting of the amino acid sequence of GVYDGEEHSV (SEQ ID NO: 303), wherein the peptide is in a complex with an MHC molecule, wherein the cancer is selected from the group consisting of hepatocellular carcinoma (HCC), brain cancer, kidney cancer, pancreatic cancer, colon or rectal cancer, and leukemia.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 90.0
- Lexical Diversity: 1.42
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15917159', '15362294', '15789731', '15083075', '15638687']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7338142679205475
- 35 USC 102 Novelty (BERT): 0.5152099311411541
- Combined Prediction Score: 0.7119538342426082
- Mean Citation Score: 326.151742
- Max Citation Score: 327.15237
- Similarity Product: 301.7808476808446

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test